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Background. Lung volumes in obese patients are reduced significantly in the postoperative
period. As the effect of different analgesic regimes on perioperative spirometric tests in obese
patients has not yet been studied, we investigated the effect of thoracic epidural analgesia and
conventional opioid-based analgesia on perioperative lung volumes measured by spirometry.
Methods. Eighty-four patients having midline laparotomy for gynaecological procedures success-
fully completed the study. Premedication, anaesthesia and analgesia were standardized. The
patients were given a free choice between epidural analgesia (EDA) (n=42) or opioids (n=42)
for postoperative analgesia.We performed spirometry tomeasure vital capacity (VC), forced vital
capacity, peak expiratory flow, mid-expiratory flow and forced expiratory volume in 1 s at
preoperative assessment, 30–60 min after premedication and 20 min, 1 h, 3 h and 6 h after
extubation.
Results. Baseline values were all within the normal range. All perioperative spirometric values
decreased significantly with increasing body mass index (BMI). The greatest reduction in VC
occurred directly after extubation, but was less in the EDA group than in the opioid group: mean
of 23(SD 8)% versus 30(12)% (P<0.001). In obese patients (BMI>30) the difference in VC was
significantly more pronounced than in patients of normal weight (BMI<25): 45(10)% versus
33(4)% (P<0.001). Recovery of spirometric values was significantly quicker in patients receiving
EDA, particularly in obese patients.
Conclusion.We conclude that EDA should be considered in obese patients undergoing midline
laparotomy to improve postoperative spirometry.
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Introduction
The prevalence of obesity is increasing and about one-third
of the population of industrialized countries is at least 20%
overweight.1 Obesity is a risk factor for postoperative pul-
monary complications since it predisposes to the formation
of atelectasis and thus contributes to pulmonary morbidity
by jeopardizing respiratory function.2 3 There is a significant
negative correlation between perioperative spirometric tests
and obesity.4 Despite some controversies,5 many anaesthe-
tists consider perioperative epidural anaesthesia (EDA) as an
important part of a multimodal approach to improving
patient outcome and analgesia rather than relying solely
on systemic opioid administration.6 This may be particularly
important for obese patients undergoing extensive laparo-
tomies, although the superiority of EDA in obese patients
has not yet been proved. Since there are no studies assessing
the impact of body mass index (BMI=weight [kg]/height2
[m2]) and different analgesic regimens on perioperative
spirometry following midline laparotomy, we proposed
that, compared with systemic opioids, EDA for periopera-
tive analgesia would reduce the magnitude of postoperative
deterioration in lung function in obese more than in non-
obese patients.
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Methods
Study population
The study was approved by the Ethics Committee of the
University of Basel. Informed written consent was obtained
from each patient before inclusion. We prospectively
included 99 adult female patients (ASA I–II) scheduled
for midline laparotomy for extensive abdominal gynaecolo-
gical procedures. Patients who were ASA III only because of
their morbid obesity, but without other systemic disease,
were also included in the study. They were informed
about the advantages, disadvantages and risks of EDA
and opioid analgesia by independent anaesthetists not
involved in this study. After making a free choice between
EDA (n=48, EDA group) and opioids (n=51, opioid group),
we invited the patients to participate in the study. For ethical
reasons (adverse effects and particularly the neurological
risks of thoracic EDA are of greater consequence for the
patients than the risks of systemic opioid analgesia) the
allocation to the different analgesic regimens was not ran-
domized, and therefore the study was conducted using an
observational design. We excluded patients who were preg-
nant, suffered from bronchial asthma requiring regular ther-
apy, had cardiac disease associated with dyspnoea >NYHA
II or had severe psychiatric disorders.
General anaesthesia
In both groups, premedication consisted of oral midazolam
7.5 mg given 30–60 min before surgery. In the EDA group,
EDA was initiated after local infiltration according to our
routine using an 18 gauge Tuohy needle and a 20 gauge
multiport epidural catheter inserted at the T7–T8 or T8–T9
interspace. After a negative test dose consisting of lidocaine
2% (3 ml) with 1:200 000 epinephrine, an epidural bolus
injection of bupivacaine 15 mg and fentanyl 100 mg in
sodium chloride 0.9% (10 ml) were given. Further bolus
injections of bupivacaine 0.5% followed according to clin-
ical needs. In both groups, general anaesthesia was induced
with propofol 2 mg kg1 and fentanyl 2 mg kg1 i.v. Tra-
cheal intubation was facilitated by atracurium 0.5 mg kg1
i.v. Anaesthesia was maintained with nitrous oxide 66% in
oxygen and propofol by infusion using the Bristol formula
(10 mg kg1 h1 for the first 10 min, 8 mg kg1 h1 for a
further 10 min and thereafter 6 mg kg1 h1 or adjusted to
individual needs).7 Ventilation was controlled using an
ADU Ventilator (Datex Ohmeda, S/5 ADU Helsinki,
Finland) with a circle system. Repeated doses of fentanyl
were given during surgery as necessary based on clinical
signs (heart rate, arterial pressure, pupil size and sweating),
but not within 60 min of the estimated end of surgery. To
have the patient fully alert and cooperative for spirometry,
we substituted sevoflurane for propofol 30–60 min before
the estimated end of surgery as this was considered, on the
basis of clinical observations, to allow for a more rapid
recovery.4 Increments of atracurium 5 mg i.v. were given
to maintain muscle relaxation which was monitored by train-
of-four stimulation. Neostigmine 2.5 mg and glycopyrrolate
0.5 mg i.v. were given as needed to antagonize residual
neuromuscular block. Before extubation of the trachea,
four equal twitches in the train-of-four without tetanic
fade (50 Hz over 5 s) were required as well as recovery
of consciousness (eye opening on demand), protective air-
way reflexes and adequate spontaneous ventilation.
Postoperative pain management
In both groups, postoperative basic analgesia consisted of
paracetamol 1000 mg rectally or orally every 6 h starting
directly after the operation. In the EDA group, a continuous
infusion of epidural bupivacaine 0.125% with fentanyl
2 mg ml1 was administered. The infusion rate was adjusted
to obtain a sensory level of T5 (range 5–10 ml h
1) and
adequate analgesia. Adequate analgesia was defined as a
pain score <20 mm while coughing, which was assessed
on the 100 mm visual analogue scale (VAS), where 0 mm
represented no pain or no dyspnoea while 100 mm indicated
the worst possible pain or dyspnoea). If pain persisted in the
EDA group despite a sufficient sensory level, as a first mea-
sure an additional epidural dose of fentanyl 100 mg in
sodium chloride 0.9% (10 ml) was given. In both groups,
according to our standards, increments of methadone 2 mg
i.v. were given to the patients in order to achieve adequate
analgesia. The total dose of methadone given to each patient
was neither limited nor weight adjusted.
Spirometry
Spirometry was standardized with each patient in a 30
head-up position using a Vitalograph 2120 (Vitalograph,
Hamburg, Germany). At the pre-anaesthetic visit, a baseline
spirometry measurement was taken (T0) after a thorough
demonstration of the correct usage. Vital capacity (VC),
forced vital capacity (FVC), forced expiratory volume in
1 s (FEV1) mid-expiratory flow (MEF25–75) and peak expira-
tory flow (PEF) were measured and the FEV1/FVC ratio was
calculated. At each assessment time, spirometry was per-
formed at least three times to be able to meet the criteria of
the European Respiratory Society (ERS)8 and the best meas-
urement was recorded. When the patient arrived in the
operating theatre (about 30–60 min after premedication),
we repeated spirometry (T1) after initiation of effective
EDA (where applicable) and before induction of anaesthesia
in order to compare the effect of premedication alone with
the effect of premedication plus effective EDA on spiro-
metric tests. After extubation, as soon as the patient was
alert and fully cooperative, pain and dyspnoea were assessed
during coughing using the VAS before and, if necessary,
after analgesic therapy. Pain was not assessed during the VC
manoeuvre itself. As soon as a patient had a VAS pain score
<20 mm during coughing (all patients met this criterion
within 20 min of extubation), we performed spirometry
for the third time (T2). Spirometric assessments were
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repeated in the postanaesthetic care unit at 1 h (T3), 3 h (T4)
and 6 h (T5) after extubation. Prior to each assessment, as
soon as the patients were free from pain during coughing,
methadone requirements were documented and sensory levels
of EDA were evaluated. All postoperative measurements,
including spirometry, were performed by postanaesthetic
care unit nurses trained to use the spirometer but unaware of
the study hypothesis and otherwise not involved in this study.
Statistical analysis
We measured the weight and height of each patient to obtain
the exact BMI. In order to quantify the effect of obesity, we
allocated the patients according to their BMI as follows:
normal weight (BMI<25), mildly obese (BMI 25–30) and
obese (BMI>30). To allow for comparisons between the
patients and the groups, pulmonary function values were
calculated as the percentage deviation from baseline (T0).
To compare data within the groups, repeated-measure ana-
lysis of variance (ANOVA) was applied. To compare data
between the groups, a Wilcoxon rank-sum test was per-
formed. For post hoc comparisons, a Bonferroni test was
applied and probability values were calculated. The
Spearman rank correlation test was used to calculate the
correlation coefficients between spirometric measurements
and BMI as the BMI data were skewed. A P-value <0.05 was
considered significant. The Statview for Windows software
package (SAS Institute Inc., Cary, NC, USA, Version 5.0.1)
was used for statistical calculations.
Results
We recruited 99 women scheduled for laparotomy. The
planned surgery was altered for three patients, seven subjects
declined to continue and measurements were unsatisfactory
in five. Consequently, we present data for 84 female patients
with 42 individuals per group (Table 1). The number of
patients for each BMI group was as follows: normal weight
(EDA n=25, opioid n=24), mildly obese (EDA n=8, opioid
n=11) and obese (EDA n=9, opioid n=7). Patients with
unacceptable spirometric tracings did not differ in age or
weight from those with acceptable measurements nor did
they have extreme values of BMI. The distribution of non-
smokers between the groups was similar with 38 (90%) in the
EDAgroupand35(83%)in theopioidgroup.Thesmokers (2–
15 pack-years) were evenly distributed over the BMI range
with a minor tendency towards lower BMI. Antagonism of
muscle relaxation was necessary in only two patients of the
opioid group and in none of the EDA group. All patients met
the extubation criteria. The mean duration of surgery was 180
(SD 45) min, with a maximum of 260 min.
Vital capacity
The baseline VC values were within the normal range. After
premedication, there was a small but significant decrease in
VC compared with baseline values in all patients (Table 2) but
there was no difference between the two groups. The decrease
was greater in those with a higher BMI, although the effect in
normal-weight patients was minimal (Fig. 1 and Table 3). In
both groups, the lowest values were found directly after extu-
bation. The opioid group showed a significantly greater
decrease in VC at all postoperative assessments as well as a
slower recovery of VC than the EDA group (Fig. 1). At every
point, VC values decreased significantly with increasing BMI
(Fig. 1). There was a significant correlation between BMI and
VC for all assessments (P<0.005).
Table 2 Absolute and relative values of vital capacity, forced vital capacity, forced expiratory flow rate in 1 s, mid-expiratory flow rate and peak expiratory flow rate
for patients with epidural or opioid analgesia. Values are mean (SD). Changes are shown as percentage of preoperative value. All changes within the groups were
significant (repeated measure ANOVA); the significances between the groups (Wilcoxon rank-sum test) are indicated (*significant; NS, not significant)
VC FVC FEV1 MEF25–75 PEF
EDA Opioid EDA Opioid EDA Opioid EDA Opioid EDA Opioid
Preoperative (T0) 3.1 (0.5) 3.1 (0.5) NS 3.1 (0.5) 3.1 (0.5) NS 2.6 (0.4) 2.6 (0.5) NS 4.0 (0.7) 4.0 (0.7) NS 368 (48) 368 (50) NS
Premedication (T1) 2.9 (0.5) 3.0 (0.6) NS 2.9 (0.5) 2.9 (0.5) NS 2.5 (0.4) 2.5 (0.5) NS 3.7 (0.7) 3.8 (0.6) NS 338 (48) 348 (53) NS
Change
(% value at T0)
5 (3) 5 (4) NS 6 (3) 5 (4) NS 6 (4) 5 (3) NS 7 (4) 5 (4) * 8 (4) 5 (4) *
After surgery (T2) 2.4 (0.6) 2.2 (0.6) * 2.4 (0.6) 2.2 (0.6) * 2.0 (0.5) 1.8 (0.5) * 3.0 (0.6) 2.8 (0.6) * 279 (54) 257 (62) *
Change
(% value at T0)
23 (8) 30 (12) * 23 (8) 30 (12) * 24 (8.6) 31 (12) * 24 (8) 30 (11) * 25 (8) 31 (11) *
At 60 min (T3) 2.4 (0.6) 2.3 (0.6) NS 2.4 (0.6) 2.2 (0.6) * 2.1 (0.5) 1.9–0.5 * 3.1 (0.6) 2.8 (0.6) * 281 (55) 261 (60) *
Change
(% value at T0)
22 (8) 29 (11) * 22 (8) 29 (11) * 23 (9.1) 29 (11) * 24 (8) 29 (11) * 24 (8) 29 (11) *
At 180 min (T4) 2.5 (0.6) 2.3 (0.6) * 2.5 (0.6) 2.2 (0.6) * 2.1 (0.5) 1.9 (0.5) * 3.2 (0.6) 2.8 (0.6) * 291 (53) 265 (61) *
Change
(% value at T0)
19 (8) 28 (11) * 20 (8) 28 (11) * 21 (8.9) 28 (11) * 21 (8) 29 (11) * 21 (8) 28 (11) *
At 360 min (T5) 2.6 (0.6) 2.3 (0.6) * 2.5 (0.6) 2.2 (0.6) * 2.2 (0.5) 1.9 (0.5) * 3.3 (0.6) 2.9 (0.6) * 301 (53) 270 (64) *
Change
(% value at T0)
17 (8) 27 (13) * 17 (8) 27 (12) * 18 (8.8) 28 (12) * 18 (8) 27 (12) * 19 (8) 27 (12) *
Table 1 Anthropometric data for 84 patients undergoing midline laparotomy
with thoracic epidural analgesia (n=42) or with an opioid-based regime (n=42) as
postoperative pain relief. Values are median (range, SD)
EDA Opioid
Age (yr) 48 (26–88) 46 (23–90)
BMI 24 (5.6) 24 (5.8)
Obesity, epidural analgesia and spirometry
123
Other spirometric values
The baseline values of all other variables (FVC, FEV1,
MEF25–75 and PEF) were within normal ranges. At each
measurement, they changed in parallel with VC with the
exception of the EDA group showing lower PEF and
MEF25–75 values after premedication (T1) than the opioid
group (Table 2). All these parameters correlated
significantly with BMI (P<0.005). The ratio FEV1/FVC
did not change in either group throughout the study period.
Intraoperative opioid requirement, postoperative
pain scores and pain relief
There were no differences in pain scores between the
groups when spirometry was performed; the maximum
VAS value was 20 mm. There was no correlation between
the VAS scores and the reduction in spirometric
measurements in either group of patients. During the
whole study period, no patient in either group complained
of dyspnoea.
There were significant differences between the groups
regarding intraoperative and postoperative opioid require-
ments. Mean intraoperative fentanyl doses were 0.30
(0.10) mg in the EDA group versus 0.62 (0.17) mg in the
opioid group.
Postoperatively, seven patients in the EDA group
received a single dose of epidural fentanyl 100 mg, while
four patients received a single dose of methadone 2 mg i.v.
Postoperative analgesic requirements were higher in the
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Fig 1 Differences (%) of vital capacity of the group with epidural analgesia (EDA group, white bars) and the group with opioid analgesia (opioid group,
black bars) at the different times of spirometric assessment divided into three groups according to body mass index (BMI<25, BMI 25–30 and BMI>30).
*P<0.05; n.s., not significant.
Table 3 Absolute values and changes of vital capacity for patients with EDA or opioid analgesia according to body mass index. Values are mean (SD) or change
(percentage of preoperative value). All changes within the groups were significant (repeated measure ANOVA): the significances between the groups (Wilcoxon rank
sum test) are indicated (*significant; NS, not significant)
BMI<25 BMI 25–30 BMI>30
EDA (n=25) Opioid (n=24) EDA (n=8) Opioid (n=11) EDA (n=9) Opioid (n=7)
Preoperative (T0) 3.3 (0.4) 3.2 (0.5) NS 3.1 (0.5) 3.2 (0.5) NS 2.6 (0.4) 2.9 (0.7) NS
Premedication (T1) 3.1 (0.4) 3.1 (0.5) NS 2.9 (0.4) 2.9 (0.5) NS 2.4 (0.4) 2.7 (0.7) NS
Change (% value at T0) 4 (2) 3 (3) NS 5 (2) 7 (2) NS 10 (2) 10 (3) NS
After surgery (T2) 2.7 (0.5) 2.4 (0.5)
* 2.3 (0.5) 2.2 (0.6) * 1.8 (0.3) 1.6 (0.5) *
Change (% value at T0) 19 (7) 25 (8) * 24 (6) 33 (11) * 33 (4) 45 (10) *
At 60 min (T3) 2.7 (0.5) 2.5 (0.5)
* 2.3 (0.5) 2.1 (0.6) * 1.8 (0.3) 1.7 (0.5) *
Change (% value at T0) 17 (6) 23 (7) * 25 (6) 33 (11) * 31 (4) 42 (8) *
At 180 min (T4) 2.8 (0.5) 2.5 (0.5)
* 2.3 (0.5) 2.2 (0.6) * 1.9 (0.3) 1.7 (0.4) *
Change (% value at T0) 15 (6) 22 (7) * 24 (6) 31 (10) * 27 (3) 42 (6) *
At 360 min (T5) 2.8 (0.5) 2.5 (0.6)
* 2.5 (0.5) 2.2 (0.6) * 2.0 (0.3) 1.7 (0.5) *
Change (% value at T0) 13 (7) 21 (9) * 20 (5) 31 (12) * 24 (4) 42 (8) *
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opioid group, as indicated by mean methadone doses of 0.9
(1.1) mg immediately after extubation, 4.5 (2.2) mg between
T2 and T3, 4.1 (2.1) mg between T3 and T4, and 4.4 (1.9) mg
between T4 and T5. This resulted in a total methadone dose
within the first six postoperative hours of 14 (3.6) mg for the
opioid group compared with 0.2 (0.7) mg for the EDA group.
There was no correlation between the opioid consumption
and the reduction of VC within either the EDA or the opioid
groups.
Discussion
Spirometric measurements as a measure of
respiratory function
Although spirometry is only a surrogate measure of respira-
tory function in the perioperative period, it is an accurate,
reproducible and simple investigative tool that can be used
easily in the immediate perioperative period in both the
operating theatre and the postanaesthetic care unit. Healthy
patients may be able to cope with less than a full VC range
during normal tidal breathing, but important respiratory
functions such as coughing and deep breathing may be sig-
nificantly impaired in critically ill patients or in patients with
pre-existing pulmonary disease. In order to increase the
accuracy of spirometry, factors that potentially interfere
with breathing and volition, such as pain, should be elimi-
nated or at least minimized as far as possible in order to
produce reliable measurements.
Effect of premedication and initiation of
effective EDA
The effect of premedication was similar to that shown in a
previous study,4 although EDA was introduced as a new vari-
able. Premedication resulted in a BMI-related reduction of
VC with no significant difference between the groups and no
further change by effective EDA. However, there was a com-
paratively wide range of individual responses to the effect of
premedication. VC is known to be a good index of respiratory
muscle strength in patients with neuromuscular disorders.9
Benzodiazepines have a spinally mediated relaxant action on
respiratory muscles9 and could have been expected to affect
respiration, with obese patients being more affected because
of their greater work of breathing.10 Another explanation for
the impairment is sedation induced by midazolam that could
have interfered with spirometric performance. However,
sedation or lack of volition would have affected both obese
and non-obese patients equally, although we did not include
an alternative measure of the patient’s ability to cooperate and
perform maximally. Moreover, changes in MEF25–75 values,
which depend less on patient cooperation than PEF values,
were in parallel to the changes in PEF values during the
whole study period.11 The observation that premedication
with benzodiazepines resulted in a marked reduction of VC
in obese patients indicates that this class of patient should
be given either no or a reduced dose of premedication.
Thus, if premedication is given to obese patients, they should
be closely observed in the preoperative period for signs of
respiratory impairment.
Surprisingly, EDA did not influence spirometric measure-
ments (except for a reduction of PEF and MEF25–72 values),
even though initiation of EDA may have accounted for some
degree of muscle relaxation as shown by changes in dynamic
rather than static spirometric measurements of respiratory
function.12 13
Anaesthesia and immediate postoperative
respiratory function
As previously described,4 the lowest spirometric values are
observed during the first assessment after extubation. The
decrease in VC, FVC, FEV1, MEF25–75 and PEF followed
the same pattern (Table 2), and the FEV1/FVC ratio did not
change. This suggests a restrictive pattern of respiratory
compromise in the immediate postoperative period, as pre-
viously described.4 14
Postoperative impairment of spirometric measurements
was probably not related to insufficient cooperation since
all patients were alert and fully compliant within 20 min
of extubation. Additionally, any lack of cooperation would
have affected the whole study population to a comparable
degree. The reduction of spirometric volumes observed in
our study may have been caused by impaired respiratory
mechanics, obesity and atelectasis formation promoted
by general anaesthesia in the supine position, as well as
by abdominal surgery.15–17 A reduction in both inspiratory
and expiratory reserve volumes would not only have an
impact on VC,14 but might interfere directly with the ability
to cough effectively as a result of decreased inspiratory
capacity and thus predispose to respiratory complications.2 14
Body mass index and immediate postoperative
respiratory function
As previously reported,4 the compromise of spirometric
measurements correlated significantly with increasing
BMI, persisted over the entire study period and was more
severe in obese patients. Six hours after an operation, the
mean VC reduction in the opioid group was 42% for obese
but only 21% for normal-weight patients. These data dif-
fered significantly from those obtained within the EDA
group, in which there was a mean reduction in VC of
24% for obese and 13% for normal-weight patients.
Thoracic epidural analgesia and respiratory
function
The effect of EDA on spirometric measurements is
controversial. High-thoracic EDA was shown to decrease
spirometric measurements by blocking intercostal muscle
innervation.18 19 A recent study showed a 25–30% decrease
in FVC and FEV1 after initiation of EDA in patients under-
going cardiac surgery. This decrease was mainly attributable
to change of position, since baseline measurements
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performed in the sitting position were compared with sub-
sequent measurements in the supine position.20 In contrast
with the latter results, and in line with our study, others have
not found that EDA has any influence on spirometry or lung
dynamics.21–24
During forced expiration (e.g. spirometry), the principal
expiratory muscles are those of the abdominal wall and, to a
lesser extent, the internal intercostal muscles. EDA with
sensory levels extending from approximately T4 to L1 is
likely to be accompanied by some degree of muscle paraly-
sis, even if low concentrations of local anaesthetics are
used,13 and is more likely to block the muscles of the abdom-
inal wall (innervation T6–L1) than the diaphragm (C3–C5) or
the intercostal muscles (T1–T11). This blockade of abdom-
inal muscles because of low-thoracic EDA is reflected by a
reduction of the dynamic parameters PEFR and MEF25–75,
which depend more on active exhalation, but is without
significant changes in comparatively static spirometric mea-
surements (e.g. VC).19 25–27 Even a subtle decrease in
abdominal muscle tone because of EDA will affect dynamic
parameters before impairing static parameters.
Some older studies show a reverse relationship between
reduced spirometric measurements and increased post-
operative complication rates.28 Despite the lack of evid-
ence that EDA reduces in-hospital mortality, a recent large
randomized trial showed a significant reduction in postopera-
tive respiratory failure rates (23% versus 30%).5 However,
since lung volumes were not measured, this trial did not
answer the question as to whether a reduction in spirometric
values was predictive of postoperative complications.
Overall, the positive effects of EDA on spirometric tests,
which became even more important in obese patients, might
add to other benefits of EDA shown in previous studies, such
as earlier mobilization, more rapid recovery of bowel func-
tion, thus allowing oral nutrition, and less disturbance of
mental status in the elderly.29 30
Postoperative pain and respiratory function
Spirometric measurements have been used to quantify post-
operative pain.31 32 Therefore it is crucial for a patient to be
free of pain during spirometry and thus to be as close to
preoperative baseline conditions as possible to avoid factors
that affect test performance. Pain probably influenced the
results of earlier studies in which insufficient postoperative
pain relief might have contributed to a greater decrease
of VC.28 33
Although all our patients were free of pain during
coughing (VAS<20 mm), there might also have been
some degree of abdominal tension because of volume shifts
into the third space.14 The pain score during the VC
manoeuvre itself was not measured. Theoretically, reduction
of abdominal wall tension induced by EDA might result in a
decrease of diaphragmatic strain and ease displacement of
the abdominal contents during breathing, and thus might
have contributed to the measured differences between the
two techniques. Therefore inspiratory volumes would be
increased in the EDA group, improving all spirometric
measurements provided that active expiration is intact.12
Sedation induced by the larger doses of opioids required
during surgery and for postoperative analgesia might have
interfered with spirometry of subjects not receiving the ben-
efits of EDA, although there was no correlation between the
opioid requirements and spirometric performance within
the groups.
Limitations
An observational rather than a randomized study design was
used in our study. With randomization, this study would not
have been finished within a reasonable time span in our
hospital. Many patients refuse thoracic EDA for fear of
neurological complications after being informed about its
risks. In consequence, the patients opted for systemic opioid
analgesia technique.
The potential for a selection bias was minimized by the
support of anaesthetists not involved in this study who were
responsible for giving patients preoperative information.
Patients were only asked for informed consent once they
had decided on their perioperative pain regimen. Addition-
ally, postoperative spirometry was performed by trained
nurses who were unaware of the study hypothesis and
were not involved in this study.
Our findings do not allow us to draw conclusions regard-
ing the mechanism of VC loss or to distinguish between the
loss of inspiratory and expiratory power. Nevertheless, the
primary aim of our study was to examine the potential of
different perioperative anaesthetic regimens for modifying
spirometrically measured lung volumes, and to assess
whether there were clinically relevant differences in post-
operative respiratory impairment during the immediate post-
operative period when the impact of surgical trauma and
anaesthesia are likely to peak and trigger postoperative pul-
monary morbidity.4
We conclude that obesity is an important risk factor for
perioperative impairment of spirometric measurements in
patients undergoing laparotomy. The moderate reduction
of spirometric tests induced by midazolam as premedication
was not enhanced further by EDA. The reduction postopera-
tively was significantly greater in obese than in normal-
weight patients. In all patients, the severity of postoperative
lung volume reduction measured by spirometry was reduced
by the presence of EDA and postoperative restoration of
lung volumes was significantly quicker. The use of EDA
should be considered for obese patients undergoing midline
laparotomy.
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